Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company

Scilex, a public majority-owned subsidiary of Sorrento located in Palo Alto, CA and San Diego, California, responsibly develops and brings branded pharmaceutical products to market using technologies designed to maximize quality of life. We are uncompromising in our focus to become the global pharmaceutical leader committed to social, environmental, economic, and ethical principles.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercialization of non-opioid pain management products for treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Working together to make a difference in the world of pain management.

The merger of Scilex and Semnur Pharmaceuticals creates a Global Leader in Non-Opioid Pain Management. Scilex Holding, Inc is 100% owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals.

Yorkville Advisors

Frazier Healthcare Partners

Press Release: Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

https://lnkd.in/gpbw77nS

#ScilexPR

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in U.S. in the first quarter of 2024

Press Release: Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy

https://lnkd.in/gpbw77nS

#ScilexPR


🦃 Wishing you a Thanksgiving filled with joy, gratitude, and an extra helping of pumpkin pie! 

Happy Thanksgiving to our hardworking and dedicated employees🙏😊


Press Release: Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®

https://lnkd.in/gpbw77nS

#ScilexPR

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	21.03M -	23.56M 12.01%	31.32M 32.92%	38.03M 21.45%	46.74M 22.90%
cost of revenue	5.80M -	2.15M 62.96%	3.63M 69.10%	10.80M 197.11%	19.83M 83.63%
gross profit	15.23M -	21.41M 40.58%	27.68M 29.29%	27.24M 1.61%	26.92M 1.18%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	64.70M -	42.97M 33.58%	50.58M 17.71%	64.89M 28.30%	119.60M 84.30%
research and development expenses	85.52M -	9.96M 88.35%	9.20M 7.63%	9.05M 1.60%	12.75M 40.78%
other expenses	3.71M -	3.74M 0.67%	3.74M 0%	3.92M 4.92%	-7.19M 283.30%
cost and expenses	159.73M -	58.82M 63.18%	67.16M 14.17%	88.67M 32.03%	152.17M 71.62%
operating expenses	153.93M -	56.67M 63.18%	63.52M 12.09%	77.87M 22.59%	132.35M 69.96%
interest expense	16.89M -	13.12M 22.34%	39.76M 203.17%	9.60M 75.85%	1.07M 88.88%
ebitda	-134.49M -	-31.48M 76.59%	-32.06M 1.84%	-46.67M 45.58%	-101.28M 117.01%
operating income	-138.69M -	-35.26M 74.58%	-35.84M 1.65%	-50.63M 41.29%	-105.43M 108.22%
depreciation and amortization	4.21M -	3.78M 10.29%	3.78M 0.05%	3.96M 4.82%	4.15M 4.67%
total other income expenses net	-39.90M -	-12.31M 69.14%	-52.58M 327.00%	27.27M 151.87%	-8.89M 132.58%
income before tax	-178.59M -	-47.57M 73.36%	-88.42M 85.86%	-23.36M 73.58%	-114.32M 389.38%
income tax expense	2K -	-53K 2,750%	5K 109.43%	4K 20%	13K 225%
net income	-178.59M -	-47.52M 73.39%	-88.42M 86.08%	-23.36M 73.58%	-114.33M 389.35%
weighted average shs out	141.10M -	17.25M 87.77%	132.86M 670.19%	134.23M 1.03%	130.30M 2.93%
weighted average shs out dil	141.10M -	17.25M 87.77%	132.86M 670.19%	134.23M 1.03%	130.30M 2.93%
eps	-1.27 -	-2.75 116.54%	-0.67 75.64%	-0.17 74.63%	-0.88 417.65%
epsdiluted	-1.27 -	-2.75 116.54%	-0.67 75.64%	-0.17 74.63%	-0.88 417.65%

NASDAQ:SCLX

Scilex Holding Company

Last Close

1.70

26/07 20:00

Market Cap

335.20M

Beta: 0.46

Volume Today

552.92K

Avg: 653.46K

PE Ratio

−2.04

PFCF: −15.31

Preview